Latest UCB News & Updates

See the latest news and media coverage for UCB. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
UCB

Global biopharmaceutical company for neurological and immune‑mediated diseases

ucb.com
Headquarters
Brussels, Belgium
Founded year
1928
Company type
Private company
Number of employees
5,000–15,000

Last updated

Latest news about UCB

In short: UCB expanded its immunology and neurology pipelines through multi-billion dollar acquisitions and strong 2025 financial growth driven by Bimzelx.

Company announcements

  • UCB

    UCB announces strategic alliance with Cancer Research UK

    The alliance accelerates novel cancer therapies development, expanding prior collaboration with two new projects. Partners share costs; UCB retains commercialization rights.

  • UCB

    UCB acquires IMIDomics Inc.’s Patient Insight Business

    The acquisition integrates 18+ years of clinical data and the IMID Biobank into UCB’s R&D, establishing a Barcelona hub for precision medicine.

  • UCB

    UCB announces acquisition of Candid Therapeutics

    The deal, worth up to $2.2 billion, adds cizutamig, a novel T-cell engager for autoimmune diseases, to UCB's immunology pipeline. Expected to close by Q3 2026.

  • UCB

    UCB announces acquisition of IMIDomics’ Patient Insight Business

    The deal grants access to comprehensive multi-omic datasets for immune-mediated inflammatory diseases, enhancing drug target identification and patient stratification.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about UCB

Track UCB and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

UCB competitors & trending companies

Browse news for competitors to UCB and other trending companies.